January 30, 2023 02:51 PM ESTUpdated January 31, 10:30 AM
Deals
Manufacturing

Charles Riv­er se­cures $50M ac­qui­si­tion of drug dis­cov­ery tech com­pa­ny

Tyler Patchen

News Reporter

Over the past sev­er­al years, Mass­a­chu­setts-based con­trac­tor Charles Riv­er Lab­o­ra­to­ries has been busy on the M&A front, with the lat­est, $50 mil­lion buy­out com­ing Mon­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Vac­cine biotechs say they’ve been told to stop next-gen Covid work un­der a Biden-era project

Re­cent FDA staff cuts to de­lay drug hear­ing de­ci­sion by months, agency tells Van­da

Drug­mak­ers stock­pile in­ven­to­ry in the US, seek­ing to get ahead of Trump tar­iffs

Up­dat­ed: Roche’s $50B US in­vest­ment in­cludes pre­vi­ous build an­nounce­ments

Bris­tol My­er­s' schiz­o­phre­nia drug fails Phase 3 tri­al for ad­junc­tive treat­ment

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times